All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is the clinical significance of secondary-AML-type mutations in de novo AML?
What is the clinical significance of secondary-AML-type mutations in de novo AML
Fernandez discusses the importance of the identification of AML mutations and the prognostic effects on patients (e.g., NPM1 and TP53 mutations). Fernandez outlines the incidence of mutations, and discusses a presentation from the EHA 2022 Congress about clinical and prognostic implications of secondary-AML-type mutations in de novo patients with AML.
Analysis of transcriptomic and genomic sequencing in acute myeloid leukemia
During the late breaking abstracts (LBA) session on Tuesday 10th December 2019 at the 61st American Society of Hematology (ASH) meeting, Orlando, US, Ilaria Iacobucci, St...
Treatment of older or unfit patients with AML
Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.
Subscribe to get the best content related to AML delivered to your inbox